N4 Pharma Plc

N4’s commercial strategy is to advance a pipeline of products through clinical proof of concept and then partner to take the products through the relevant regulatory pathway studies to regulatory approval.  

Sign up to our mailing list below to stay on top of all news.

Our business

Regulatory news

Leadership team

About Us

Updates

AIM Rule 26

Investors Home

Investors

Home

Open Sans

Our revenues come from licensing Nuvec® for developing gene therapy, oncology treatments and vaccines. We are actively looking for partners.

The stages in the partnership process are typically:

Partnership collaborations to test the delivery system

If you’d like further information or have any queries, please 

Pharmaceutical and Biotech companies are spending millions to develop novel treatments for cancer and hard-to-treat diseases using scientifically engineered siRNA/DNA/RNA molecules. In the body, nucleic acids need to be successfully delivered intracellularly with sufficient drug payload to be effective.

N4 Pharma’s breakthrough silica nanoparticle Nuvec® has been consistently proven to protect the payload and deliver it into the cell. Nuvec® particles have a unique irregular surface structure that simply and effectively traps and protects the siRNA/RNA/DNA as it travels to the cells. Once inside the cell, it is released to deliver a localised response.

To date, companies have tended to use existing commercially available delivery systems such as lipid nanoparticles, but unlike Nuvec®, these were not designed for working with nucleic acids and although they can also produce good responses they can also induce release of systemic inflammatory cytokines, meaning the patient can feel unwell, plus they may cause liver toxicity.

Nuvec® is safe and well tolerated even at high doses and can be delivered intravenously, sub cutaneously or intra muscular.

With siRNA, Nuvec® can produce a strong dose response curve showing significant cellular transfection from very low doses, meaning the amount of expensive siRNA needed to be effective can be significantly reduced. Nuvec® can also load multiple siRNA onto the same particle to utilise multiple pathways within the same cell.

N4 Pharma has acquired the exclusive rights to commercialise a granted patent from the University of Queensland and has its own patent application for the use of Nuvec® to improve the performance of viral vectors.